XOMA (NASDAQ:XOMA) Rating Lowered to “Sell” at StockNews.com

XOMA (NASDAQ:XOMA) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

Separately, HC Wainwright reissued a “buy” rating and set a $123.00 target price on shares of XOMA in a research note on Tuesday.

XOMA Price Performance

Shares of XOMA opened at $25.74 on Wednesday. XOMA has a one year low of $18.57 and a one year high of $35.00. The stock’s fifty day moving average is $29.20 and its 200-day moving average is $27.94. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The firm has a market capitalization of $303.29 million, a price-to-earnings ratio of -7.40 and a beta of 0.92.

Insider Transactions at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its stake in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. Rhumbline Advisers boosted its position in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Barclays PLC increased its stake in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares in the last quarter. Ellsworth Advisors LLC acquired a new stake in XOMA during the 3rd quarter worth about $516,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after buying an additional 1,968 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.